Satraplatin

Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial

- Overall survival results do not achieve statistical significance - GPC Biotech schedules conference call for Wednesday, October 31st, 8:30 AM ET/13:30 CET BOULDER, Colo., MARTINSRIED, Germany, MUNICH, Germany and PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ ...

GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial

... announced that the Phase 3 SPARC trial evaluating satraplatin for the treatment of hormone-refractory prostate c...taxel, RenaZorb(TM), SPI-1620 and SPI-205." About satraplatin In 2002, Spectrum licensed the global rights to G...a Co., Ltd. Spectrum licensed worldwide rights to satraplatin from Johnson Matthey PLC. About Spectrum Pharmace...

Satraplatin Benefits Hormone Refractory Prostate Cancer Patients

...ort from Columbia University on Phase III trial on satraplatin has shown: * Highly Statistically Significant ... Chemotherapy Treatment, including Taxotere? * satraplatin was Well Tolerated with Myelosuppression the Most ..., all of which require intravenous administration, satraplatin is an orally bioavailable compound and is given as...

Satraplatin in Medical Technology

Additional Data From Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress

Patients treated with Satraplatin Demonstrated Statistically Significant Improvement in Pain Response and PSA Response Rates BERLIN, March 22, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation and GPC Biotech AG today announced additional data from the double-blind, randomized satraplatin Phase ...

Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association

-- Median time to pain progression is 66.1 weeks for the satraplatin arm compared with 22.3 weeks for the placebo arm -- Hazard ratio of 0.64 (95% CI: 0.51-0.79, p<0.001), representing a 36% reduction in the relative risk of pain progression MARTINSRIED/MUNICH, Germany, May 21, 2007 /PRNewswire-Fi...

Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting

- All pre-specified subset analyses of progression-free survival in the SPARC Phase 3 trial consistently demonstrate a reduction in relative risk of disease progression for patients receiving satraplatin. These analyses included prior Taxotere use, geographies, as well as presence or absence of pai...

Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting

-- All pre-specified subset analyses of progression-free survival in the SPARC Phase 3 trial consistently demonstrate a reduction in relative risk of disease progression for patients receiving satraplatin. These analyses included prior Taxotere use, geographies, as well as presence or absence of pa...

Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting

...istic Interaction between the Oral Platinum Analog satraplatin and Erlotinib In preclinical studies, satraplatin was active in a number of various tumor models and... lines to satraplatin was examined. Conclusion satraplatin is synergistic with erlotinib, which may be relate...

Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting

...esented or published, including Phase III data for satraplatin and Thalidomide, encouraging Phase II data for Amr...pm; McCormick Place Convention Center, S Hall A2 satraplatin Oral Presentation: satraplatin demonstrates significant clinical benefits for the...

Satraplatin in Biological Technology

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... Cellular Immunotherapy II-59 Spectrum Announces Positive Outcome of satraplatin Trial on HRPC Patients II-59 Panacea Pharmaceuticals Identifies Blo...plera Corporation II-69 GPC Biotech and Celgene Terminate Agreement for satraplatin II-70 EUSA Acquires Cytogen Corporation II-70 Eisai Acquires MGI Ph...

Pharmion Corporation Announces 2007 Operating Results

...1, 2007 include a charge of $8 million for a milestone payment triggered by the acceptance of Pharmion's marketing authorization application (MAA) for satraplatin for the treatment of second-line hormone-refractory prostate cancer by the European Medicines Agency (EMEA). Research and development expenses total...

Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP

...tudies; (2) that the Company continued to evaluate satraplatin using the disputed endpoint; (3) that the Company ... with the disputed primary endpoint supporting its satraplatin New Drug Application ("NDA"); (4) that the FDA's e...h the NDA would not allow the FDA to conclude that satraplatin was more effective than placebo in terms of overal...

Finkelstein Thompson LLP Announces GPC Biotech AG Investigation

...Complaint further alleges that, under increased pressure to gain FDA marketing approval, Defendants used improper testing methods to determine whether satraplatin was safe and effective. On July 24, 2007, the FDA disclosed that it had unanimously recommended against the approval of Satraplatin. The market respo...